By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Visterra, Inc. 

One Kendall Square
Suite B3301
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-1070 Fax: 617-498-1073


SEARCH JOBS


Industry
Biotechnology






Company News
Visterra, Inc. Announces Publication In The Journal Cell, Demonstrating That Novel Antibody, VIS513, Broadly Neutralizes All Four Serotypes Of Dengue Virus In Preclinical Studies 7/17/2015 9:11:24 AM
Visterra, Inc. Announces Presentation Of Data At International Influenza Meeting On The Efficacy Of VIS410 For Treatment Of A Deadly Strain Of Avian Influenza 6/2/2015 1:28:20 PM
Visterra, Inc. Announces Presentation Of Data At International Influenza Meeting On The Efficacy Of VIS410 For Treatment Of A Deadly Strain Of Avian Influenza 6/2/2015 11:33:00 AM
Visterra, Inc. Partners With A*STAR To Develop VIS513, A Monoclonal Antibody For Dengue 5/22/2015 10:42:49 AM
Visterra, Inc. Announces Additions To Its Management Team And Board Of Directors 10/31/2014 9:21:33 AM
Cambridge Biotech Visterra, Inc. Reels In $30 Million 10/2/2014 5:58:47 AM
Visterra, Inc. To Present Data At ICAAC On VIS513, Its Humanized Monoclonal Antibody That Targets A Conserved Site On The Dengue Virus E Protein 9/3/2014 11:05:35 AM
Visterra, Inc. To Present Data At ICAAC On VIS513, Its Humanized Monoclonal Antibody That Targets A Conserved Site On The Dengue Virus E Protein 9/3/2014 8:53:04 AM
Visterra, Inc. To Present At The 32nd Annual J.P. Morgan Healthcare Conference 1/13/2014 7:15:21 AM
Visterra, Inc. Acquires Exclusive Patent License For Monoclonal Antibodies Against Dengue Virus From Massachusetts Institute of Technology (MIT) 12/2/2013 9:21:39 AM
12
//-->